Market Alert: Strong Nuclear Tensions in South Asia Assessing the Fallout on Global Equity Markets
FY24 Business Summary
Third Age Health (NZX: TAH) has significantly expanded its national footprint and market share during the fiscal year 2024. The company increased the number of Aged Residential Care (ARC) patients it provides care to by 18%, now supporting 12.4% of New Zealand’s ARC population across 67 facilities. Additionally, Third Age Health's combined enrolled patient population across both ARC and general practice grew by 4% to 24,969.
National Footprint and Clinical Team Expansion
FY24 Financial Summary
Chairman & CEO Report
The full-year results for FY24 reflect significant progress in creating customer value in primary medical care within ARC settings and community general practices. Process improvements and system enhancements have stabilized operations, leading to sustainable growth. Recruitment efforts have successfully attracted more clinicians, meeting growing demand and strengthening service delivery.
Key Initiatives and Improvements
Financial Performance and Future Outlook
The ARC-related business experienced strong organic growth, with revenue increasing by 39%. Community General Practices also saw revenue growth of 30%. Pricing adjustments across both ARC and General Practices helped align with rising resourcing costs.
Looking ahead, Third Age Health is optimistic about continued growth, supported by investments in processes, systems, and digital advancements. The company expects organic revenue and underlying profit in FY25 to surpass FY24’s figures, albeit at a more moderate pace. A final fully imputed dividend per share of 2.80 cents has been announced, adhering to the 75% payout ratio dividend policy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Apr 24, 2025
Apr 24, 2025
Apr 23, 2025
Apr 23, 2025
Apr 22, 2025
Apr 22, 2025
Apr 17, 2025
Apr 17, 2025
Apr 16, 2025
Apr 16, 2025
The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.